The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression.
Spravato (esketamine) has possible interactions with alcohol, some other drugs, and certain supplements. Examples include Adderall and benzodiazepines such as clonazepam (Klonopin). Talk with your ...
Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback